- Home
- ALVR vs CODA Comparison
ALVR vs CODA Comparison
Compare ALVR & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALVR
- CODA
- Stock Information
- Founded
- ALVR 2013
- CODA 1994
- Country
- ALVR United States
- CODA United States
- Employees
- ALVR N/A
- CODA N/A
- Industry
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- CODA Industrial Machinery/Components
- Sector
- ALVR Health Care
- CODA Industrials
- Exchange
- ALVR Nasdaq
- CODA Nasdaq
- Market Cap
- ALVR 87.7M
- CODA 76.0M
- IPO Year
- ALVR 2020
- CODA N/A
- Fundamental
- Price
- ALVR $0.57
- CODA $9.36
- Analyst Decision
- ALVR Sell
- CODA Strong Buy
- Analyst Count
- ALVR 5
- CODA 1
- Target Price
- ALVR $1.00
- CODA $11.00
- AVG Volume (30 Days)
- ALVR 593.0K
- CODA 75.9K
- Earning Date
- ALVR 11-12-2024
- CODA 09-16-2024
- Dividend Yield
- ALVR N/A
- CODA N/A
- EPS Growth
- ALVR N/A
- CODA N/A
- EPS
- ALVR N/A
- CODA 0.26
- Revenue
- ALVR N/A
- CODA $18,824,676.00
- Revenue This Year
- ALVR N/A
- CODA $8.20
- Revenue Next Year
- ALVR N/A
- CODA $18.67
- P/E Ratio
- ALVR N/A
- CODA $36.33
- Revenue Growth
- ALVR N/A
- CODA N/A
- 52 Week Low
- ALVR $0.52
- CODA $5.21
- 52 Week High
- ALVR $2.49
- CODA $9.89
- Technical
- Relative Strength Index (RSI)
- ALVR 37.63
- CODA 61.85
- Support Level
- ALVR $0.52
- CODA $8.15
- Resistance Level
- ALVR $0.64
- CODA $9.15
- Average True Range (ATR)
- ALVR 0.10
- CODA 0.42
- MACD
- ALVR -0.03
- CODA 0.03
- Stochastic Oscillator
- ALVR 10.28
- CODA 69.54
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
About CODA Coda Octopus Group Inc. Common stock
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. It operates in two segments: Marine Technology Business and Marine Engineering Business. The Technology Business develops proprietary solutions for both the commercial and defense subsea market. Its solutions include hardware and software for Geophysical Systems, Motion & Positioning Systems, and Real-Time Volumetric Imaging Sonar. The Engineering Business segment provides engineering services to a range of clients in the defense markets. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Marine Technology Business segment.